ASCO Annual Meeting: Melanoma

Articles

With further follow-up, lifileucel (LN-144) continued to show durable responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed on multiple therapies, including prior anti–PD-1/PD-L1 therapy

Lifileucel Continues to Show Durable Responses in Advanced Melanoma

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma efficacy results continue to show a durable response. 

Lenvatinib-Pembrolizumab Combo Improves Outcomes in Certain Patients With Advanced Melanoma

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

Nivolumab Monotherapy, With Ipilimumab Continuously Improves Outcomes in Advanced Melanoma

About 40% of patients who progressed on placebo following resection of melanoma experienced an objective response with crossover to pembrolizumab in the phase 3 EORTC 1325/KEYNOTE-054 trial.

Crossover to Pembrolizumab for Patients With Resected, Stage III Melanoma Yields Better Efficacy Vs Rechallenge

A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting. 

Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses

Progression-free survival more than doubled when relatlimab was added to nivolumab to treated patients with previously untreated, unresectable or metastatic melanoma.

Median PFS Extended in Advanced Melanoma Treated With Frontline Relatlimab/Nivolumab

Ajay K. Nooka, MD, MPH, FACP discussed the clinical benefits of belantamab mafodotin in combination with bortezomib/dexamethasone to treat multiple myeloma.

ASCO Expert Discusses Clinical Benefit of Combination for Relapsed/Refractory Multiple Myeloma

Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.

Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission

Videos

Cancer Network spoke with Paul B. Chapman, MD, of Memorial Sloan Kettering Cancer Center, about pursuing adjuvant immunotherapy for patients with melanoma.

Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma Patients

Cancer Network spoke with Hussein Tawbi, MD, PhD, of MD Anderson Cancer Center, about the efficacy and safety of the combination of nivolumab plus ipilimumab in patients with symptomatic melanoma brain metastases.

ASCO Annual Meeting: Melanoma | Conference